AVITA Medical, Inc.
RCELAvita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.: 9–10
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
RCEL Earnings Report
FQ end 2026-06 | Call: 2026-08-06 15:00:00
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is AVITA Medical, Inc.'s next FDA catalyst?→
AVITA Medical, Inc.'s (RCEL) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RCEL biotech catalysts?→
Add RCEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AVITA Medical, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.